GAIA-102

N/A

Report date: 2024/09/18 11:39:36

Base Information

Drug NameGAIA-102

Drug Alias NameGAIA-102 NK-like cellGAIA-102NPC-30

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Nature killer-like cell therapy

Mechanisms of ActionNatural killer cell replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGaia Biotechnology (Shenzhen) Co Ltd Nobelpharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesKyushu University Gaia BioMedicine Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A